Navigation Links
Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Date:10/11/2007

PARIS, October 11 /PRNewswire-FirstCall/ --

(EUR millions) 2007 2006 07/06

%Sales %Sales %

change

Southern Europe (1) 20.63 70.6 17.61 70.7 17

Other EU countries (2) 7.07 24.2 6.06 24.4 17

Other markets 1.51 5.2 1.22 4.9 24

SLIT 22.13 75.8 18.14 72.9 22

SCIT 5.96 20.4 5.60 22.5 6

Other products 1.12 3.8 1.15 4.6 (3)

Total Q3 sales 29.21 100.0 24.89 100.0 17

Southern Europe (1) 77.16 74.2 65.71 73.8 17

Other EU countries (2) 22.83 21.9 19.78 22.2 15

Other markets 4.02 3.9 3.60 4.0 12

SLIT 81.88 78.7 67.55 75.8 21

SCIT 17.78 17.1 17.23 19.3 3

Other products 4.35 4.2 4.31 4.8 1

9-month cumulated sales 104.01 100.0 89.09 100.0 17

(1) Portugal, Spain, France, Italy, Greece;

(2) Switzerland included

Sales growth and financial position

2007 3rd quarter sales registered further significant growth in all markets (+17%, vs +9% in 2006). The most vigorous market segment remained sublingual route desensitization (SLIT, +22%). Subcutaneous route sales (SCIT) increased by 6%. Cumulative sales for the first nine months of the year increased by 17% (vs +13% in 2006).

The financial position improved. Net debt declined 40% from net debt at 30 September 2006.

Significant 3rd quarter transactions and events

The new allergen production facility has been completed. Collection and validation operations are being implemented within the planned timeframe.

The market authorisation procedure for the ORALAIR(R) Grasses allergen tablet by the P.E.I. German agency is still ongoing. Management is confident the procedure will soon be completed.

Outlook for the current year

The Group now provides guidance of 12% to 14% full-year sales growth and profitability close to that of 2006 in absolute value.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes more than 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

With a registered office in France, Stallergenes markets its products in approximately 40 countries. Stallergenes realised 2006 sales of EUR 126.5 million, of which half outside France.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on Stallergenes, please visit our website: http://finance.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Midwest life science stocks sizzle in a tepid first quarter
2. CIOs looking to hire more IT workers in second quarter
3. Fiserv posts 30 percent quarterly loss
4. Sonic Foundry reports first cash-positive quarter
5. Venture capital above $6B for third straight quarter
6. Third Wave reports $5.2M third quarter loss
7. Inventions could fall prey to Monday morning quarterbacking
8. Merge fails to file quarterly financial report
9. Rexnord to slash debt after quarterly loss
10. Johnson Controls reports record quarterly sales
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... This CAST literature review and report looks at problems caused ... the economic effects in countries that are major global commodity exporters and importers, which ... risk of low level presence (LLP) puts large volumes of trade worth billions of ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... 2016 Savannah River Remediation LLC group ... NewTechBio,s NT-MAX Lake & Pond Sludge and ... in conjunction with Hexa Armor/ Rhombo cover manufactured ... Pollutant Discharge Elimination System requirements. The ... history of elevated pH levels, above 8.5, especially ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
Breaking Biology News(10 mins):